APLM Stock Summary and Trading Ideas (Apollomics - Class A | NASDAQ:APLM)

Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia. Company has three new immuno-oncology product candidates: APL-501, APL-502 and APL-801 include mono-specific and bi-specific antibodies to fight against cancer.

Apollomics - Class A trades on the NASDAQ stock market under the symbol APLM.

As of June 18, 2026, APLM stock price climbed to $17.50 with 45,474 million shares trading.

APLM has a market cap of $38.43 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, APLM traded as high as $620.00 and as low as $3.66.

APLM has outperformed the market in the last year with a price return of +188.7% while the SPY ETF gained +26.9%. However, in the short term, APLM had mixed performance relative to the market. It has underperformed in the last 3 months, returning -10.3% vs +13.5% return in SPY. But in the last 2 weeks, APLM shares have fared better than the market returning +25.0% compared to SPY -1.1%.

APLM support price is $12.86 and resistance is $15.06 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that APLM shares will trade within this expected range on the day.